Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 6/2010

01-11-2010

Selection of Ideal Candidates for Neuromodulation in Refractory Overactive Bladder

Authors: Ravi Kacker, Anurag K. Das

Published in: Current Urology Reports | Issue 6/2010

Login to get access

Abstract

Sacral neuromodulation is a minimally invasive, reversible treatment option that has been approved by the US Food and Drug Administration for patients with urgency/frequency and urge incontinence. While long-term success rates are high, the high treatment cost and the need for operative revision or explantation in cases of failure make the selection of ideal candidates particularly important. Because predictive factors for success and the exact mechanism of action are not known, physicians must rely on a preimplantation test procedure, either in the office or in the operating room, to select patients for implantation of a pulse generator. In this paper, we review the recent literature on performing a test procedure with both temporary and permanent leads and the selection of optimal candidates for sacral neuromodulation therapy.
Literature
1.
Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology of lower tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167–178CrossRefPubMed
2.
Basra RK, Wagg A, Chapple C, et al.: A review of adherence to drug therapy in patients with overactive bladder. BJU Int 2008, 102:774–779.CrossRefPubMed
3.
Yoshimura N, Seki S, Chancellor MB, et al.: Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology 2002, 59(Suppl 1):61–67CrossRefPubMed
4.
Fowler CJ, Swinn MJ, Goodwin RJ, et al.: Studies of the latency of pelvic floor contraction during peripheral nerve evaluation show that the muscle response is reflexly mediated. J Urol 2000; 163:881–883CrossRefPubMed
5.
•• Oerlemans DJ, van Kerrebroeck PE: Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn 2008, 27:28–33. This is a review of literature on sacral neuromodulation for overactive bladder and other expanding indications.CrossRefPubMed
6.
Brazzelli M, Murray A, Fraser C: Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006, 175:835–841CrossRefPubMed
7.
Schmidt RA, Jonas U, Oleson KA, et al.: Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999, 162:352–357CrossRefPubMed
8.
Leong RK, De Wachter SG, van Kerrebroeck PE: Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 2010, 84:245–253.CrossRefPubMed
9.
• van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al.: Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007, 178:2029–2034. The data in this article suggest a durable response to sacral neuromodulation for voiding dysfunction.CrossRefPubMed
10.
Sievert KD, Amend B, Gakis G, et al.: Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol 2010, 67:74–84.CrossRefPubMed
11.
Zabihi N, Mourtzinos A, Maher MG, et al.: Short-term results of bilateral S2–S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19:553–557.CrossRefPubMed
12.
Comiter CV: Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol 2003, 169:1369–1373.CrossRefPubMed
13.
•• Powell CR, Kreder KJ: Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures. J Urol 2010, 183:173–176. This was a small series with promising long-term results on sacral neuromodulation for overactive bladder in patients with painful bladder syndrome. The type of test procedure did not affect outcome.CrossRefPubMed
14.
Cohen BL, Tunuguntla HS, Gousse A: Predictors of success for first stage neuromodulation: motor versus sensory response. J Urol 2006, 175:2178–2181.CrossRefPubMed
15.
Koldewijn EL, Rosier PF, Meuleman EJ, et al.: Predictors of success with neuromodulation in lower urinary tract dysfunction: results of trial stimulation in 100 patients. J Urol 1994, 152:2071–2075.PubMed
16.
Everaert K, Kerckhaert W, Caluwaerts H, et al.: A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur Urol 2004, 45:649–654CrossRefPubMed
17.
Van Voskuilen AC, Oerlemans DJ, Weil EH, et al.: Medium-term experience of sacral neuromodulation by tined lead implantation. BJU Int 2007, 99:107–110.CrossRefPubMed
18.
Kessler TM, Madersbacher H, Kiss G: Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method. Eur Urol 2005, 47:660–665.CrossRefPubMed
19.
Weil EH, Ruiz-Cerdá JL, Eerdmans PH, et al.: Clinical results of sacral neuromodulation for chronic voiding dysfunction using unilateral sacral foramen electrodes. World J Urol 1998, 16:313–321.CrossRefPubMed
20.
Das AK, Carlson AM, Hull M; U.S. MDT-103 Study Group: Improvement in depression and health-related quality of life after sacral nerve stimulation therapy for treatment of voiding dysfunction. Urology 2004, 64:62–68.CrossRefPubMed
21.
Siegel SW, Catanzaro F, Dijkema HE, et al.: Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000, 56(6 Suppl 1):87–91.CrossRefPubMed
22.
Hijaz A, Vasavada S: Complications and troubleshooting of sacral neuromodulation therapy. Urol Clin North Am 2005, 32:65–69.CrossRefPubMed
23.
• Wantanabe JH, Campbell JD, Ravelo A, et al.: Cost Analysis of Intervention of Antimuscarinic Refractory Patients with Overactive Bladder. Urology 2010 Apr 28 [Epub ahead of print]. This study estimates US payer costs for up to 3 years for patients with overactive bladder symptoms refractory to pharmacologic therapy.
Metadata
Title
Selection of Ideal Candidates for Neuromodulation in Refractory Overactive Bladder
Authors
Ravi Kacker
Anurag K. Das
Publication date
01-11-2010
Publisher
Current Science Inc.
Published in
Current Urology Reports / Issue 6/2010
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-010-0137-1

Other articles of this Issue 6/2010

Current Urology Reports 6/2010 Go to the issue

ReviewPaper

Androgen Replacement Therapy After Prostate Cancer Treatment

OriginalPaper

Augmentation Enterocystoplasty in Overactive Bladder: Is There Still a Role?

CLINICAL TRIAL REPORT

Clinical Trials Report: Pazopanib for Advanced Renal Cell Carcinoma: Comments on the Results from the Phase 3 Study

CLINICAL TRIAL REPORT

Need for Standardization in Definition of Success in Clinical Trials on Stress Urinary Incontinence

ReviewPaper

Overactive Bladder and Pain: Management Strategies

ReviewPaper

Gene Therapy for Erectile Dysfunction: What Is the Future?